Back

Glucose-lowering therapy in type 2 diabetes with heart failure vs high HF risk: missed opportunities for prognosis-modifying treatment

11 May 2026 (14:55 - 16:12)
Organised by: Logo
Congress Presentation Part of: ePosters in risk factors and prevention (1) Diabetes and the Heart HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Vadim Medovchshikov

West Kazakhstan Marat Ospanov Medical University, Aktobe (Kazakhstan)

6 More presentations in this session

Presentation thumbnail
Prevalence of eligibility for dual GIP/GLP-1 receptor agonists among non-diabetic and overweight adults - a Portuguese community-based study
Doctor H. Santos Moreira (Porto, PT)
Abstract Slides
Presentation thumbnail
The role of the triglyceride-glucose index as a predictor of coronary artery disease severity in young patients
Doctor A. Martins (Leiria, PT)
Abstract Slides
Presentation thumbnail
Design of the asian diabetes outcomes prevention trial: biomarker-guided primary prevention and key protocol updates
Doctor C. Chandramouli (Singapore, SG)
Abstract Slides
Presentation thumbnail
GLP-1 receptor agonist-induced post-procedural gastrointestinal and biliary complications in cardiothoracic surgery
Doctor Z. Wright (Winston Salem, US)
Abstract Slides
Presentation thumbnail
Cardio-kidney-metabolic syndrome in the general population: patterns and sex-specific trajectories
Doctor R. Coenen Chelu (Rotterdam, NL)
Abstract Slides

Access the full session

Session thumbnail
ePosters in risk factors and prevention (1)

The Event

Event poster

Heart Failure 2026

11 May 2026 14:55 CET
You may be interested in
thumbnail
Webinar
Prevention of heart failure in diabetic patients at population level
thumbnail
Congress Session
Diabetes, obesity, and heart failure
thumbnail
Webinar
Diabetes and ACS - enhancing post-discharge outcomes after primary PCI

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources